Analysts Set Aemetis, Inc. (NASDAQ:AMTX) PT at $12.95

Shares of Aemetis, Inc. (NASDAQ:AMTX) have been given an average rating of “Moderate Buy” by the five analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $12.95.

AMTX has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $28.00 target price on shares of Aemetis in a research note on Friday, November 15th. Truist Financial restated a “hold” rating and issued a $3.50 target price (down from $4.00) on shares of Aemetis in a research note on Wednesday, July 31st. UBS Group decreased their price target on shares of Aemetis from $8.25 to $7.75 and set a “buy” rating for the company in a research note on Monday, August 19th. StockNews.com raised Aemetis to a “sell” rating in a research note on Wednesday, July 31st. Finally, Ascendiant Capital Markets decreased their target price on Aemetis from $20.00 to $19.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd.

Aemetis Trading Down 1.5 %

Aemetis stock opened at $4.03 on Friday. The firm has a market capitalization of $200.45 million, a PE ratio of -1.78 and a beta of 1.23. Aemetis has a 12-month low of $2.10 and a 12-month high of $7.03. The firm has a 50-day moving average price of $2.96 and a 200-day moving average price of $3.05.

Aemetis (NASDAQ:AMTX) last announced its earnings results on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.09. The business had revenue of $81.44 million for the quarter, compared to analysts’ expectations of $77.79 million. During the same quarter last year, the firm earned ($0.59) EPS. As a group, sell-side analysts predict that Aemetis will post -2.02 earnings per share for the current fiscal year.

Institutional Trading of Aemetis

Several hedge funds and other institutional investors have recently bought and sold shares of AMTX. SG Americas Securities LLC purchased a new stake in shares of Aemetis during the 1st quarter worth $60,000. Rhumbline Advisers raised its holdings in Aemetis by 2,837.1% in the second quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock worth $157,000 after purchasing an additional 50,528 shares in the last quarter. Susquehanna Fundamental Investments LLC lifted its position in shares of Aemetis by 287.4% during the second quarter. Susquehanna Fundamental Investments LLC now owns 126,078 shares of the specialty chemicals company’s stock valued at $379,000 after buying an additional 93,536 shares during the last quarter. State Board of Administration of Florida Retirement System bought a new stake in shares of Aemetis in the 1st quarter valued at about $84,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Aemetis in the 2nd quarter worth approximately $306,000. Institutional investors own 27.02% of the company’s stock.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.